

The role of Gene Mutations (*gyrA*, *parC*) in Resistance to Ciprofloxacin in Clinical Isolates of *Pseudomonas Aeruginosa*

Nasibeh Arabameri¹ , Zoheir Heshmatipour^{1*} , Shima Eftekhari Ardebili¹, Zeinab Jafari Bidhendi¹

1. Department of Microbiology, Faculty of Science, Tonekabon Branch, Islamic Azad University, Tonekabon, Iran

KEYWORDS

Ciprofloxacin, *gyrA*, Mutation, *parC*, *Pseudomonas aeruginosa*,

Scan to discover online



Main Subjects:
Microbiology

Received 13 Dec 2020;

Accepted 27 Jun 2021;

Published Online 06 Jul 2021;

[10.30699/IJP.2021.520570.2542](https://doi.org/10.30699/IJP.2021.520570.2542)

ABSTRACT

Background & Objective: *Pseudomonas aeruginosa* is an opportunistic pathogen and one of the most common causes of nosocomial infections. This bacterium's antibiotic resistance to the common fluoroquinolone antibiotics, especially ciprofloxacin, is due to mutations in the *gyrA* and *parC* genes. This study aimed to investigate the effect of the mutation in (*gyrA*, *parC*) on ciprofloxacin resistance in clinical isolates of *Pseudomonas aeruginosa*.

Methods: A total of 140 clinical samples were collected from hospitals. The samples were identified by standard biochemical tests, and the antibiotic resistance was investigated by the disk diffusion method. DNA was extracted from 30 isolates, and PCR was performed. PCR-sequencing was carried out to assess *gyrA* and *parC* mutations in drug-resistant isolates. NCBI-Blast and MEGA7 software was used to analyze the nucleotide sequences.

Results: 30 clinical isolates were 80% resistant to ciprofloxacin; meanwhile, in 21 samples, mutations were observed. 87/5% of mutations were related to *gyrA* (Thr83 → Ile), 79/16 % *parC* (Ser87 → Leu), and 4/18% (Glu91 → Lys). The antibiotic resistance to ciprofloxacin and mutations in *gyrA* and *parC* genes in resistant isolates are significantly related to each other ($P < 0.05$).

Conclusion: The mutations in the *gyrA* and *parC* genes play an essential role in resistance to ciprofloxacin in clinical isolates of *Pseudomonas aeruginosa*.

Corresponding Information:

Zoheir Heshmatipour, Department of Microbiology, Faculty of Science, Tonekabon Branch, Islamic Azad University, Tonekabon, Iran E-mail: zheshmat@gmail.com

Copyright © 2021. This is an open-access article distributed under the terms of the Creative Commons Attribution- 4.0 International License which permits Share, copy, and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, even commercially.

Introduction

Pseudomonas aeruginosa, a genus Gammaproteobacteria, belongs to the large family of *Pseudomonas* (1, 2). In the form of biofilm, this bacterium has higher pathogenicity than planktonic (3). *P. aeruginosa* is the cause of 10% of common nosocomial infections (4).

Quinolones are broad-spectrum oral antibacterial agents that are widely used in therapy. They are lightweight hydrophilic molecules that inhibit DNA replication without affecting RNA or protein synthesis in susceptible bacteria. Quinolones include four generations, of which ciprofloxacin is the second one (5, 6). The bactericidal effect of ciprofloxacin on resistant strains of *P. aeruginosa* is much more significant than other types of antibiotics that seem to treat *pseudomonas-related* infections (7, 8). Fluoroquinolones can easily enter cells through purines, often used to treat intracellular pathogens such as *Legionella pneumophila* and *Mycoplasma pneumoniae*.

In gram-negative bacteria, DNA gyrase, and gram-positive bacteria, topoisomerase IV is targeted (9, 10). The resistance of *P. aeruginosa* to fluoroquinolones,

including ciprofloxacin, can be mediated by mutations in DNA gyrase and topoisomerase IV, reducing wall permeability and increasing efflux pump expression (11-14). DNA gyrase and topoisomerase IV are tetrameric enzymes with different subunits, *gyrA*, and *parC* from DNA gyrase homologous and, *parC* and *parE* from topoisomerase IV (15, 16). Genetic, biochemical, and epidemiological studies show that DNA gyrase is the first target, and topoisomerase IV is the second target of fluoroquinolones (17, 18). Mutations in the fluoroquinolone resistance determinant region (QR-DR) in the *gyrA* and *parC* genes are the major causes of fluoroquinolone resistance in *P. aeruginosa* (19, 20). This study's purpose is to investigate the role of mutations in *gyrA* and *parC* genes in the development of ciprofloxacin resistance in clinical isolates.

Material and Methods

Sample Preparation and Identification

In 2019, 140 *P. aeruginosa* strains were collected as cross-section individuals from patients with cystic

fibrosis, urinary infections, and diabetic wounds from Imam Khomeini Hospital, Resalat Hospital, and Bouali Hospital in Tehran, Iran. Bacteria were identified from various samples, including urine, blood, wounds, pleura, CSF, and characterized using various biochemical tests, including TSI reaction, OF test, Oxidase test, Catalase test, and Sim-on citrate test following the reference protocols (19, 21). The approved isolates were stored in a -70°C freezer for further testing. All tests were done in a microbiology laboratory in Islamic Azad University, Tonekabon, Mazandaran, Iran.

Antimicrobial Susceptibility

For further molecular studies, we initially selected all ciprofloxacin-resistant strains to ensure that the strains contain the potential resistance genes. Strains were incubated in LB broth overnight at 37°C . Using antibiotic disks (CONDA, Spain), include Rifampin, Trimethoprim-sulfamethoxazole, Ampicillin-sulbactam, Ciprofloxacin, Ceftriaxone, Amikacin, Imipenem, Gentamicin, Piperacillin-tazobactam, and Ceftazidime. Antibiotic resistance was determined based on the resistance patterns of the isolates by the disk diffusion method. A concentration of 1.5×10^8 CFU/mL of each overnight fresh culture

was made individually, and an amount of $100\mu\text{L}$ were spread on Mueller-Hinton agar plates using sterile cotton swabs. Disks were placed on each plate with distinct space between to observe the inhibitory zones and incubated for another 24 h in 37°C .

Molecular Assay

The GeneMarkbio product kit extracted the DNA of 30 ciprofloxacin-resistant isolates from Taiwan. The primer sequence was examined at the NCBI website using Blast software and subsequently produced by the Danish company (Tag-Copenhagen, Denmark). The sequence and size of the primer are mentioned in [Table 1](#) (22). Following this, PCR was performed on 30 isolates and a negative control for possible contaminations. Following that, the PCR samples were sent to BIONEER, South Korea for sequencing, and then the results were analyzed using MEGA software and NCBI. The *gyrA* and *parC* genes sequence were compared with associated locus in *Pseudo-monas aeruginosa PAO1* AE004091 wild strain from NCBI GenBank as reference. Finally, the gene mutations that cause changes in the nucleotide sequence, including deletion or insertion of nucleotides, resulting in a shift in the amino acid sequence, were analyzed by MEGA7 software.

Table 1. Primers used in this study

Gene name	Nucleotide sequences	Band size	Reference
<i>gyrA</i> -F	5'-GAC GGC CTG AAG CCG GTG CAC-3'	460 bp	(22)
<i>gyrA</i> -R	5'-GCC CAC GGC GAT ACC GCT GGA-3'		
<i>parC</i> -F	5'-CAT CGT CTA CGC CAT GAG-3'	270 bp	
<i>parC</i> -R	5'-AGC AGC ACC TCG GAA TAG-3'		

Results

Antibiotic Susceptibility

The antibiotic susceptibility pattern in 30 samples out of 140, which are confirmed to be ciprofloxacin-resistant to *P. aeruginosa* using biochemical identifiers and disk diffusion assay, in random infected patients gathered from several hospitals in Tehran, as we mentioned before, showed different antibiotic resistance percentages and patterns, as shown in [Figure 1](#). Strains were collected mostly from cystic fibrosis lungs, blood, urine, and wound samples of patients regardless of their age, medical history, or gender.

Gene Screening Results

According to the results obtained from PCR products of 30 clinical samples, as shown in [Figure 2](#), the product size of *gyrA* is 460 bp, and *parC* is 270 bp.

Findings of frequency percentages were analyzed by descriptive statistical methods such as Chi-Square, considering that the P-value from the frequency of antibiotic resistance and susceptibility to ciprofloxacin and mutations in *gyrA* and *parC* genes (0.023) is less

than 0.05. Therefore, there is a significant relationship between ciprofloxacin antibiotic resistance and mutations in *gyrA* and *parC* genes.

The point mutations in 24 ciprofloxacin-resistant isolates are as follow: 87.5% of mutations in codon 83 *gyrA* gene (Thr83 → Ile), 79.16% in codon 87 *parC* gene (Ser87 → Leu), and 4.18% in codon 91 *parC* gene (Glu91 → Lys). Association between antibiotic susceptibility and mutations in the *gyrA* and *parC* genes in 30 clinical isolates is shown in [Table 3](#) and [Figure 3](#). These mutations are caused by the mismatch of nucleotides in a location of two strands (23), as shown in [Figure 4](#). Besides, no mutations were observed in any of the sensitive isolates. The number and location of mutations in *gyrA* (Thr83 → Ile) and *parC* (Ser87 → Leu) genes were the same in 6 blood samples, 11 urine samples, and three tracheal samples. While in 1 isolate from the wound sample, a mutation in the *parC* gene was confirmed in codon 91 (Glu91 → lys) and codon 87 (Ser87 → Leu), as shown in [Table 3](#).




Fig. 1. Results of *Pseudomonas aeruginosa* antibiotic resistance using Disk Diffusion Antibiotic Sensitivity test (The Kirby-Bauer test); abbreviations refer to rifampin (RIF), trimethoprim-sulfamethoxazole (SXT), ampicillin-sulbactam (SAM), ciprofloxacin (CIP), ceftriaxone (CRO), amikacin (AMK), imipenem (IPM), gentamicin (GEN), piperacillin-tazobactam (TZP), ceftazidime (CAZ).




Fig. 2. Results of electrophoresis of PCR products carrying *parC* and *gyrA* genes on 3% agarose gel

Table 2. The connection between ciprofloxacin sensitivity and mutations in *gyrA* and *parC* in 30 clinical specimens of *Pseudomonas aeruginosa*

	R(Resistant)	I(Intermediate)	S(Sensitive)	Total
Number of isolates	24	0	6	30
Mutation only in <i>gyrA</i>	1	0	0	1
Mutation only <i>parC</i>	1	0	0	1
Mutations in both <i>gyrA</i> and <i>parC</i> genes	19	0	0	19
No mutation	3	0	6	9




Fig. 3. Ciprofloxacin resistance and gene mutation percentages in *P. aeruginosa* isolates



Fig. 4. Sequence elements of *gyrA* and *parC* gene nucleotides

Table 3. Types and positions of *gyrA* and *parC* mutations in *Pseudomonas aeruginosa* clinical specimens

Amino acid changes	Mutation	codon	Number	Gene
Thr-Ile	ACC-ATC	83	21	<i>gyrA</i>
Ser-Leu	TCG-TTG	87	19	<i>parC</i>
Glu-Lys	GAG-AAG	91	1	

Discussion

Pseudomonas aeruginosa is the most common pathogen in the genus *Pseudomonas* and is the third most common nosocomial infection after *Staphylococcus aureus* and *Escherichia coli* (13, 24). This opportunistic pathogen has acquired high resistance to antibiotics, causing various infections, and is responsible for one of the deadliest sepsis among gram-negative bacteria by entering the bloodstream (25-27).

In recent years, extensive use of antibiotics causes resistance to broad-spectrum antibiotics among pathogenic bacteria. Multidrug-resist-ant strains (MDR) are currently the main problem in treating nosocomial infections in different hospital wards, such as burn centers or intensive care (28-30). The

mechanism of action of ciprofloxacin is inhibition of DNA gyrase and topoisomerase IV. DNA gyrase is the bacterial topoisomerase II that controls the topology of the double helix of DNA during the replication and translation process (31-33).

However, several cases of resistance of *Pseudomonas* isolates to this group of antibiotics have been reported. The most important mechanism of bacterial resistance to fluoroquinolones is the mutation in genes encoding DNA gyrase (*gyrA*) and topoisomerase IV (*parC*) (34).

P. aeruginosa antibiotic resistance has been the subject of many studies with different results regarding the surveys' time and geographical location. The

antibiotic resistance ratio of the current research is as follow: rifampin 100%, cotrimoxazole 96.6%, ampicillin sulbactam 83.3%, ciprofloxacin 80%, ceftriaxone 66.6%, amikacin 66.6%, imipenem 63.3%, gentamicin 60%, Piperacillin tazobactam 50%, and ceftazidime 43.3%. In contrast, a study supervised by Ekrami and Kalantar in 2007 on 182 strains of *P. aeruginosa* isolated from burn patients showed 100% resistance to ciprofloxacin, gentamicin, amikacin, tobramycin, and ceftazidime,(35) which differs from the present study; this may be due to differences in the time and type of isolations. In 2007, Sadari *et al.* examined 186 isolated samples and reported 74.2% resistance to ceftazidime, 38.2% to imipenem, and 49.2% to ciprofloxacin(6). However, in the present study, ciprofloxacin resistance is 30% greater. It could be due to differences in the annual use of antibiotics and different physicians' diagnoses in timely treating infection.

In studies done by Ziyuan Yang *et al.* in southern China in 2015 (36) and Nouri *et al.* in Tabriz in 2016 (37) on the clinical isolation of ciprofloxacin-resistant *P. aeruginosa*, mutations in codon 83 of the *gyrA* gene, which converts the amino acid threonine to isoleucine, and mutations in the codon 87 of the *parC* gene, which changes the amino acid serine to leucine, played a significant role in resistance to ciprofloxacin. In addition to the above mutations, another mutation in the *parC* gene changes the amino acid glutamine to lysine in the present study. The findings are almost identical, and this slight difference may be related to sample collection and time variability.

In another study in Japan by Kobayashi *et al.* (2013), the cause of fluoroquinolone resistance in clinical strains of *P. aeruginosa* was caused by mutations in the *gyrA* (Thr83 → Ile), *parC* (Ser87 → Leu) genes, and overexpression of the efflux pump. This research on mutations in *gyrA* and *parC* genes is the same as the present study (38); however, there is a noticeable difference in antibiotic resistance to Ciprofloxacin, which may be due to geographical differences and arbitrary use of antibiotics in our country.

In Denmark (2000), Shah Jalal *et al.* researched on fluoroquinolone-resistant isolates found that the efflux pump is more effective than studied genes in terms of developing resistance in isolates from cystic fibrosis patients (33). With few studies in other countries, it has been shown that in strains isolated from cystic fibrosis patients, mutations in the *gyrA* and *parC* genes play a less important role than efflux pumps in fluoroquinolone resistance (39).

In Lebanon in 2013, Selma *et al.* reported 19 mutations in the *gyrA* and *parC* genes in ciprofloxacin-resistant *P. aeruginosa* strains (40). In Bulgaria in

2014, Estavov *et al.* identified mutations in *gyrA*, *parC*, and *MexR*, which were in the *gyrA* gene at codon 83, in the *parC* gene codons 87 and 136, and the *MexR* gene at codons 126 and 44. Finally, they realized that mutations in the *gyrA* gene were present in all ciprofloxacin-resistant strains of *P. aeruginosa* (41, 42). In this mutation, converting the polar amino acid threonine to a non-polar amino acid and hydrophobic isoleucine *gyrA* (Thr83 → Ile), the structure of DNA gyrase is altered, resulting in a decrease in the enzyme's tendency to react with antibiotics, eventually leading to drug resistance (18). Several studies have been performed on the *gyrA* gene, resulting in mutations in codons 83 and 87, including (Thr83 → Ile), (Asp87 → Asn) and (Asp87 → Tyr) (10, 26). While in the present study, only one mutation was observed in *gyrA* because of the dissimilarity in the type of clinical samples, time, and geographical area.

Conclusion

Based on the data obtained from other studies and present research, it was established that *Pseudomonas aeruginosa*, due to its genetic, is potentially receptive to a variety of genes such as transposons and plasmids, and therefore can quickly become resistant to antibiotics. Thereby, due to this organism's capabilities in acquiring resistance to various antibiotics, continuous monitoring of changes in bacterial susceptibility is essential. Improper use of antibiotics, especially fluoroquinolones, is a risk factor for this bacterium's resistance to medicine in Iran. Because *P. aeruginosa* is an opportunistic pathogen in hospital settings, these isolates should be detected in clinical laboratories to provide appropriate treatment for infections to prevent their spread. Regarding two genes encoding *gyrA* and *parC* that were investigated in this study, further studies should be performed on other possible genes that are involved in the development of ciprofloxacin resistance in order to achieve more comprehensive and complete results, and find better outcomes comparing phenotypic and genotypic methods.

Acknowledgements

This research has been supported by the Students' Research Center of Islamic Azad University, Tonekabon Branch.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

- Thermus-Advances in Research and Application 2012 Edition ScholarlyBrief - Google Books.
- Bridier A, Briandet R, Thomas V, Dubois-Brissonnet F. Resistance of bacterial biofilms to disinfectants: A review. *Biofouling*. 2011;27:1017-32. [DOI:10.1080/08927014.2011.626899]
- Akasaka T, Tanaka M, Yamaguchi A, Sato K. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of *Pseudomonas aeruginosa* isolated in 1998 and 1999: Role of target enzyme in mechanism of fluoroquinolone resistance. *Antimicrobial Agents and Chemotherapy*. 2001;45:2263-8. [DOI:10.1128/AAC.45.8.2263-2268.2001]
- Bergan T, Dalhoff A, Thorsteinsson S. A review of the pharmacokinetics and tissue penetration of ciprofloxacin. *Ciprofloxacin A new 4-quinolone* Findlay R ed, Sieber and McIntyre, Hong Kong. 1985:23-6.
- Castora FJ, Vissering FF, Simpson MV, editors. The effect of bacterial DNA gyrase inhibitors on DNA synthesis in mammalian mitochondria. *BBA - Gene Structure and Expression*; 1983. [DOI:10.1016/0167-4781(83)90090-8]
- Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. *Microbiology and Molecular Biology Reviews*. 1997;61:377-92. [DOI:10.1128/61.3.377-392.1997]
- Oncul O, Acar A, editors. Bacterial infections in burn patients. *Indian Journal of Medical Research*; 2008.
- Dean Laura S. Principles and Practice of Anesthesiology, 2nd Edition *Anesthesiology*. 1999;90:639-40. [DOI:10.1097/0000542-199902000-00054]
- Rees CED, Green LH, Goldman E, Loessner MJ. Phage identification of bacteria. *Practical Handbook of Microbiology*, Third Edition. 2015:99-114. [DOI:10.1201/b17871-10]
- Henrichfreise B, Wiegand I, Pfister W, Wiedemann B. Resistance mechanisms of multiresistant *Pseudomonas aeruginosa* strains from Germany and correlation with hypermutation. *Antimicrobial Agents and Chemotherapy*. 2007;51:4062-70. [DOI:10.1128/AAC.00148-07]
- Higgins PG, Fluit AC, Milatovic D, Verhoef J, Schmitz FJ. Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of *Pseudomonas aeruginosa*. *International Journal of Antimicrobial Agents*. 2003;21:409-13. [DOI:10.1016/S0924-8579(03)00009-8]
- Hooper DC. Mechanisms of action and resistance of older and newer fluoroquinolones. *Clinical Infectious Diseases*. 2000;31. [DOI:10.1086/314056]
- Jawetz, Melnick, & Adelberg's Medical Microbiology, 28e | AccessMedicine | McGraw Hill Medical 2013. 399-406 p.
- Kamel GM, Ezz Eldeen NA, El-Mishad MY, Ezzat RF. Susceptibility pattern of *Pseudomonas aeruginosa* against antimicrobial agents and some plant extracts with focus on its prevalence in different sources. *Global Veterinaria*. 2011;6:61-72.
- Kim SR, Komano T. The plasmid R64 thin pilus identified as a type IV pilus. *Journal of Bacteriology*. 1997;179:3594-603. [DOI:10.1128/jb.179.11.3594-3603.1997]
- Kobayashi H, Isozaki M, Fukuda T, Anzai Y, Kato F. Surveillance of Fluoroquinolone-Resistant Clinical Isolates of *Pseudomonas aeruginosa*. 2013. [DOI:10.4236/ojmm.2013.32022]
- Lambert PA. Mechanisms of antibiotic resistance in *Pseudomonas aeruginosa*. *Journal of the Royal Society of Medicine, Supplement*. 2002;95:22-6.
- Lee JK, Lee YS, Park YK, Kim BS. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of *Pseudomonas aeruginosa*. *International Journal of Antimicrobial Agents*. 2005;25:290-5. [DOI:10.1016/j.ijantimicag.2004.11.012]
- Malekzadeh F. *Microbiology*. 2016:409-20.
- Mirsalehian A, Feizabadi M, Akbari Nakhjavani F, Jabal Ameli F, Goli H. Prevalence of extended spectrum beta lactamases among strains of *pseudomonas aeruginosa* isolated from burn patients. *Tehran University Medical Journal*. 2008;66:333-7.
- Polyvinyls_Advances_in_Research_and_Appl.
- Mohammad Hosseini N, Taherpour, Masoumeh, Louthat, Bahram, Mehrafi, Mohammad Hassan and Fournodi, Alireza. Synthesis of cyclopropyl-fluoro-dihydro-methoxy-tinyl-yl, hydroxyiminoethyl methylpiperazine, IL-oxinquinol carboxylic acid with antimicrobial effect. *Journal of Applied Chemistry Research*. 2009.
- Mouneimné H, Robert J, Jarlier V, Cambau E. Type II topoisomerase mutations in ciprofloxacin-resistant strains of *Pseudomonas aeruginosa*. *Antimicrobial Agents and Chemotherapy*. 1999;43:62-6. [DOI:10.1128/AAC.43.1.62]
- Murray PR, Rosenthal KS, Kobayashi G. (PDF) *Medical Microbiology* 2020.
- Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. *Genome Research*. 2001;11:863-74. [DOI:10.1101/gr.176601]
- Nouri R, ... MAR-JoA, Undefined. Effect of QRDR mutations on ciprofloxacin resistance in clinical isolates of *Pseudomonas aeruginosa*. *jarumsarumsacir*. 2016.
- Roddy JA. *Medical bacteriology* 2012. 269-77 p.
- Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. *Chemistry and Biology*. 2010;17:421-33. [DOI:10.1016/j.chembiol.2010.04.012]
- Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria, (2000).
- Horieh Saderi1 ZK, Parvizi Owlia1, Mohammad Ali Bahar2, Seyed Mohammad Bagher Akhavi Rad1. Phenotypic Detection of Metallo-beta-lactamase Producing *Pseudomonas aeruginosa* Strains Isolated from Burned Patients. *Iranian Society of Pathology*. 2008;3:20-5.

31. Salma R, Dabboussi F, Kassaa I, Khudary R, Hamze M. GyrA and parC mutations in quinolone-resistant clinical isolates of *Pseudomonas aeruginosa* from Nini Hospital in north Lebanon. *Journal of Infection and Chemotherapy*. 2013;19:77-81. [DOI:10.1007/s10156-012-0455-y]
32. Savov E, Trifonova A, Todorova I, Gergova I, Borisova M, Ananieva M, et al. Assesment of the Resistance of Clinical Isolates *Pseudomonas Aeruginosa* to Quinolones. *Trakia Journal of Science*. 2014;12:221-6. [DOI:10.15547//tjs.2014.03.001]
33. Shahcheraghi F, Nikbin VS, Feizabadi MM. Prevalence of ESBLs genes among multidrug-resistant isolates of *pseudomonas aeruginosa* isolated from patients in Tehran. *Microbial Drug Resistance*. 2009;15:37-9. [DOI:10.1089/mdr.2009.0880]
34. Jalal S, Ciofu O, Høiby N, Gotoh N, Wretling B. Molecular mechanisms of fluoroquinolone resistance in *Pseudomonas aeruginosa* isolates from cystic fibrosis patients. *Antimicrobial Agents and Chemotherapy*. 2000;44:710-2. [DOI:10.1128/AAC.44.3.710-712.2000]
35. Smith S, Ganiyu O, John R, Fowora M, Akinsinde K, Odeigah P. Antimicrobial resistance and molecular typing of *Pseudomonas aeruginosa* isolated from surgical wounds in Lagos, Nigeria. *Acta Medica Iranica*. 2012;50:433-8.
36. Tohidpour A, Peerayeh SN, Najafi S. Detection of DNA Gyrase Mutation and Multidrug Efflux Pumps Hyperactivity in Ciprofloxacin Resistant Clinical Isolates of *Pseudomonas aeruginosa*. *J Med Microbiol Infect Dis*. 2013;1:1-7.
37. Harrigan WF. *Topley and Wilson's Microbiology and Microbial Infections*, 9th edn.: BMJ Publishing Group; 1998. 194-5 p. [DOI:10.1046/j.1365-2621.1998.33201913.x]
38. Tsukayama DT, Loon HJV, Cartwright C, Chmielewski B, Fluit AC, Werken CVD, et al. The evolution of *Pseudomonas aeruginosa* during antibiotic rotation in a medical intensive care unit: The RADAR-trial. *International Journal of Antimicrobial Agents*. 2004;24:339-45. [DOI:10.1016/j.ijantimicag.2004.04.011]
39. Wang DD, Sun TY, Hu YJ. Contributions of efflux pumps to high level resistance of *Pseudomonas aeruginosa* to ciprofloxacin. *Chinese Medical Journal*. 2007;120:68-70. [DOI:10.1097/00029330-200701010-00013]
40. Yang X, Xing B, Liang C, Ye Z, Zhang Y. Prevalence and fluoroquinolone resistance of *pseudomonas aeruginosa* in a hospital of South China. *International Journal of Clinical and Experimental Medicine*. 2015;8:1386-90.
41. Morello JA. *Zinsser Microbiology*. JAMA: The Journal of the American Medical Association. 1981;245:1170. [DOI:10.1001/jama.1981.03310360056032]
42. Mahmoudi H, Zare Fahim N, Alikhani MY, Shokohizadeh L. Investigation of Antimicrobial Effect of Berberine on Ciprofloxacin and Imipenem Resistance *Acinetobacter baumannii* Isolated from Hamadan Hospitals. *Iranian Journal of Medical Microbiology*. 2020;14(1):44-54. [DOI:10.30699/ijmm.14.1.44]

How to Cite This Article

Arabameri, N., Heshmatipour, Z., Eftekhar Ardebili, Sh., Jafari Bidhendi, Z. The role of gene mutations (*gyrA*, *parC*) in resistance to ciprofloxacin in clinical isolates of *Pseudomonas aeruginosa*. *Iran J Pathol*, 2021; 16(4): 426-432. doi: 10.30699/IJP.2021.520570.2542